• Beigene Ltd ONC.OQ reported a quarterly adjusted loss of $1.87​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.20. The mean expectation of eleven analysts for the quarter was for a loss of $1.02 per share. Wall Street expected results to range from $-1.63 to 46 cents per share.

• Revenue rose 28.2% to $1.00 billion from a year ago; analysts expected $1.04 billion.

• Beigene Ltd's reported EPS for the quarter was a loss of $1.87​.

• The company reported a quarterly loss of $121.35 million.

• Beigene Ltd shares had risen by 40.2% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 12.7% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Beigene Ltd is $285.00

This summary was machine generated from LSEG data February 27 at 12:26 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)